A Phase 1b/2 Study Of Docetaxel And Prednisone, With Or Without ISIS 183750 (an eIF4E Inhibitor), In Patients With Castrate-Resistant Prostate Cancer
||Seth Cohen, MD
| Time frame of study:
|Location of Study:
Beth Israel Medical Center
St.Luke's-Roosevelt Hospital Center
Continuum Cancer Research Program
ISIS 183750 is an experimental drug, which has not been approved by the Food and Drug Administration. After it is tested in animals, an experimental drug, such as ISIS 183750, has to be tested to see if it works in people. It is not known if ISIS 183750 will be beneficial to you or anyone else. ISIS 183750 is designed to reduce the amount of a specific protein (eukaryotic translation initiation factor 4E; eIF4E) that your body produces, which might contribute to prostate cancer. The purpose of this research study is to see if reducing the amount of eIF4E that your body produces will improve your prostate cancer or delay its worsening. The purpose of Part 2 of the study is to see how well ISIS 183750 treats your prostate cancer when given in combination with docetaxel, a drug that is approved by the national health authorities for treating patient with prostate cancer.
- Male of at least 18 years old
- Prostate cancer that has come back or gotten worse after medical or surgical castration
- Cannot have a medical condition associated with active bleeding or are using anticoagulants (blood thinners)
- Do not have another type of cancer
- Is not being treated with other cancer drugs
- Have not had specific cancer treatments in the past
Please call for more information.